Foreign CROs suspending participating in clinical trials in Russia

Foreign contract research companies (CROs) are suspending participating in clinical trials in Russia after the exodus of global drugmakers from the clinical research market in the country earlier this year, reports The Pharma Letter’s local correspondent.

According to the recent report by the Russian Kommersant business paper, in January-November 2023, the share of studies with the involvement of a CRO amounted to 20.5%, which is 4.1 % less than a year ago, and 10.1% less than in 2021.

According to Svetlana Zavidova, executive director of the Russian Association of Clinical Research Organizations, while the number of studies involving CROs is not entirely indicative, (since not all pharmaceutical companies identify the organization involved), such dynamics reflect the real picture in the market.